Discipline of Psychiatry & Mental Health, UNSW, Sydney, New South Wales, Australia.
University of Wollongong, Wollongong, New South Wales, Australia.
BMJ Open. 2023 Oct 27;13(10):e073893. doi: 10.1136/bmjopen-2023-073893.
Children and adolescents are increasingly prescribed antipsychotic medications off-label in the treatment of behavioural disorders. While antipsychotic medications are effective in managing behavioural issues, they carry a significant risk of adverse events that compromise ongoing physical health. Of particular concern is the negative impact antipsychotic medications have on cardiometabolic health. Interventions that aim to modify lifestyle habits have the potential to alleviate the adverse effects of antipsychotic medication by enhancing weight management, increasing physical activity, promoting better nutritional practices, improving dietary habits and promoting healthier sleep patterns and sleep hygiene. However, a comprehensive review has not been performed to ascertain the effectiveness of lifestyle interventions for children and adolescents who are at increased risk of antipsychotic-induced compromises to their physical health.
This systematic review will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Four databases will be searched without any year constraints to identify randomised controlled trials that are published in the English language and report a lifestyle intervention compared with usual care with any physical health outcome measure. Trial registers and results repositories will be scoured to identify additional studies. Two reviewers will independently conduct screening, data extraction and quality assessment and compare the results. Quantitative data will be synthesised, where appropriate, through a random-effects meta-analysis model. Otherwise, data will be reported in a qualitative (narrative) synthesis. Heterogeneity will be quantified using the I statistic. The Cochrane Risk of Bias 2 tool will be used for risk of bias assessment. The Grading of Recommendations, Assessment, Development and Evaluation system will be used to evaluate the cumulative body of evidence.
Ethics approval is not required. The publication plan will target high-impact, peer-reviewed journals that fall under the scope of Psychiatry and Mental Health.
CRD42022380277.
儿童和青少年越来越多地在行为障碍的治疗中开处方使用非标签抗精神病药物。虽然抗精神病药物在治疗行为问题方面非常有效,但它们也存在重大的不良反应风险,会损害患者的身体健康。特别值得关注的是,抗精神病药物对心脏代谢健康的负面影响。旨在改变生活方式习惯的干预措施有可能通过加强体重管理、增加身体活动、促进更好的营养实践、改善饮食习惯以及促进更健康的睡眠模式和睡眠卫生,来减轻抗精神病药物的不良影响。然而,目前尚未进行全面审查,以确定生活方式干预对存在因抗精神病药物导致身体健康受损风险的儿童和青少年的有效性。
本系统评价将遵循系统评价和荟萃分析的首选报告项目的指导原则。将在四个数据库中进行搜索,不限制年份,以确定发表在英文期刊上的随机对照试验,这些试验报告了与常规护理相比的生活方式干预措施,以及任何身体健康结果的衡量指标。试验登记处和结果存储库将被仔细搜索,以确定其他研究。两位评审员将独立进行筛选、数据提取和质量评估,并比较结果。将通过随机效应荟萃分析模型对适当的定量数据进行综合。否则,将以定性(叙述)综合的形式报告数据。使用 I 统计量来量化异质性。Cochrane 偏倚风险 2 工具将用于评估偏倚风险。推荐分级、评估、发展和评估系统将用于评估累积证据体。
不需要伦理批准。出版计划将针对属于精神病学和心理健康范围的高影响力、同行评审期刊。
PROSPERO 注册号:CRD42022380277。